These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25296980)

  • 21. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice.
    Zhang P; Lai ZL; Chen HF; Zhang M; Wang A; Jia T; Sun WQ; Zhu XM; Chen XF; Zhao Z; Zhang J
    J Exp Clin Cancer Res; 2017 Dec; 36(1):190. PubMed ID: 29273065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo inhibition of human Fanconi anemia head and neck squamous carcinoma by a phytonutrient combination.
    Roomi MW; Kalinovsky T; Roomi NW; Niedzwiecki A; Rath M
    Int J Oncol; 2015 May; 46(5):2261-6. PubMed ID: 25695860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway.
    Cao S; Xia M; Mao Y; Zhang Q; Donkor PO; Qiu F; Kang N
    Int J Oncol; 2016 Nov; 49(5):2075-2087. PubMed ID: 27667173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma.
    Yan M; Xu Q; Zhang P; Zhou XJ; Zhang ZY; Chen WT
    BMC Cancer; 2010 Aug; 10():437. PubMed ID: 20716363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer.
    Kumar B; Yadav A; Hideg K; Kuppusamy P; Teknos TN; Kumar P
    PLoS One; 2014; 9(3):e93208. PubMed ID: 24675768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to Centchroman.
    Singh N; Zaidi D; Shyam H; Sharma R; Balapure AK
    PLoS One; 2012; 7(6):e37736. PubMed ID: 22768036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
    Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
    Oncotarget; 2016 Jan; 7(3):3186-200. PubMed ID: 26672603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
    Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
    Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
    Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo.
    Gu X; Song X; Dong Y; Cai H; Walters E; Zhang R; Pang X; Xie T; Guo Y; Sridhar R; Califano JA
    Clin Cancer Res; 2008 Mar; 14(6):1840-8. PubMed ID: 18347187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
    Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
    Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
    Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
    Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
    Zhu DW; Yuan YX; Qiao JK; Yu C; Yang X; Wang LZ; Zhang ZY; Zhong LP
    Cancer Lett; 2015 Jan; 356(2 Pt B):773-80. PubMed ID: 25449438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.